CORDIS
EU research results

CORDIS
English EN
Immune Signatures for Therapy Stratification in Major Mood Disorders

Immune Signatures for Therapy Stratification in Major Mood Disorders

Objective

Objective: MOODSTRATIFICATION brings together 11 partners (psychiatrists, immunologists, epidemiologists, industry) from 7 countries stratifying patients with a major depressive episode on the basis of leukocyte immune profiles. The immune profiles were found in two previous EU projects, which also delivered the novel concept, that T cell defects with episodes of chronic mild inflammation are a causal factor for a large part of mood disorders. The immune profiles determine therapy choice with (combinations of) conventional and novel therapies with immune modulators (e.g. anti-inflammatory and T cell enforcement therapies). On the basis of recent data we expect that the present poor response rates of about 50% to anti-depressant therapy will improve considerably to 80-90%. Mood disorders are complex diseases with a high prevalence (12-20%) and are the second highest contributor to the number of years lived with disability worldwide.
Work plan: MOODSTRATIFICATION firstly uses the large data sets and biobank of the two previous EU projects to further refine the already found immune profiles. Therefore the proposal further integrates existing and newly collected multidimensional, longitudinal clinical and laboratory data (-omics, FACS and serum multi-analytes) from these projects for further immune network analysis and computational modelling also taking female-male differences into account. Technologies to easily determine the immune profiles (a relatively small multi-analyte panel, Q-PCR kits on PAXGENE material) will together with industries be developed. Thereafter the efficacy of two novel T cell enforcing therapeutic approaches and the new concept of depression stratification on the basis of the immune profiles will be validated in three clinical proof-of-principle studies. Various national and international patient associations will be actively involved.
Novelty: This is the first lab-based therapy stratification in psychiatry made ready for the clinic.

Programme(s)

H2020-EU.3.1.1. - Understanding health, wellbeing and disease

Topic(s)

SC1-PM-02-2017 - New concepts in patient stratification

Call for proposal

H2020-SC1-2017-Two-Stage-RTD

See other projects for this call

Funding Scheme

RIA - Research and Innovation action
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Address

Dr Molewaterplein 40
3015 Gd Rotterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 066 250

Website

Contact the organisation

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

Germany

EU Contribution

€ 428 750

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 101 250

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 623 500

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 471 750

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 688 125

OSPEDALE SAN RAFFAELE SRL

Italy

EU Contribution

€ 486 562,50

UNIVERSITAET ULM

Germany

EU Contribution

€ 411 500

PRONTO DIAGNOSTICS LTD

Israel

EU Contribution

€ 460 000

ADVANCED PRACTICAL DIAGNOSTICS

Belgium

EU Contribution

€ 446 500

AARHUS UNIVERSITET

Denmark

EU Contribution

€ 480 500

ILTOO PHARMA

France

EU Contribution

€ 299 062,50

Project information

Grant agreement ID: 754740

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    30 June 2022

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 5 963 750

  • EU contribution

    € 5 963 750

Coordinated by:

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

Download

PDF XML

Last update: 18 January 2018

Record number: 212672